Stefan Walzer
Research Subjects
Stefan Walzer has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Daniel Droeschel
MArS Market Access and Pricing Strategy GmbH, Weil am Rhein, Germany ; Riedlingen University, SRH FernHochschule, Riedlingen, Germany
2 shared publicationsHélène Chevrou-Séverac
Nestle Health Science, Vevey, Switzerland
2 shared publications- Lutz-Michael Vollmer
MArS Market Access & Pricing Strategy GmbH
2 shared publications Mark Nuijten
Ars Accessus Medica BV, Jisp, Amsterdam, the Netherlands
2 shared publications- Roman Spelsberg
MArS Market Access & Pricing Strategy GmbH
2 shared publications Alain Vergnenegre
Pole Sante Publique, Limoges, France
1 shared publication
Latest Publications
- 2 June 2022
- Published by Springer Nature
- p. 165-197
Digitale Gesundheitsanwendungen und ihre Evidenzgrundlage
- 2 June 2022
- Published by Springer Nature
- p. 165-197
Digitale Gesundheitsanwendungen und ihre Evidenzgrundlage
- 11 May 2022
- Published by Springer Nature
- p. 69-83
Reimbursement and Pricing
- 11 May 2022
- Published by Springer Nature
- p. 1-3
Introduction
- 11 May 2022
- Published by Springer Nature
- p. 33-42
Digital Health Applications: DiGAs—Pathway to Reimbursement
- 11 May 2022
- Published by Springer Nature
- p. 33-42
Digital Health Applications: DiGAs—Pathway to Reimbursement
- 11 May 2022
- Published by Springer Nature
- p. 43-58
Inpatient Market Access for Digital Health Care
- Open Access
Economic Evaluation of Individualized Nutritional Support for Hospitalized Patients with Chronic Heart Failure
Background Malnutrition is a highly prevalent risk factor in hospitalized patients with chronic heart failure (CHF). A recent randomized trial found lower mortality and improved health outcomes when CHF patients with nutritional risk received individualized nutritional treatment. Objective To estimate the cost-effectiveness of individualized nutritional support in hospitalized patients with CHF. Methods This analysis used data from CHF patients at risk of malnutrition (N = 645) who were part of the Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial (EFFORT). Study patients with CHF were randomized into (i) an intervention group (individualized nutritional support to reach energy, protein, and micronutrient goals) or (ii) a control group (receiving standard hospital food). We used a Markov model with daily cycles (over a 6-month interval) to estimate hospital costs and health outcomes in the comparator groups, thus modeling cost-effectiveness ratios of nutritional interventions. Results With nutritional support, the modeled total additional cost over the 6-month interval was 15,159 Swiss Francs (SF). With an additional 5.77 life days, the overall incremental cost-effectiveness ratio for nutritional support vs. no nutritional support was 2625 SF per life day gained. In terms of complications, patients receiving nutritional support had a cost savings of 6214 SF and an additional 4.11 life days without complications, yielding an incremental cost-effectiveness ratio for avoided complications of 1513 SF per life day gained. Conclusions On the basis of a Markov model, this economic analysis found that in-hospital nutritional support for CHF patients increased life expectancy at an acceptable incremental cost-effectiveness ratio.
Open AccessEconomic Evaluation of Individualized Nutritional Support for Hospitalized Patients with Chronic Heart Failure
Background Malnutrition is a highly prevalent risk factor in hospitalized patients with chronic heart failure (CHF). A recent randomized trial found lower mortality and improved health outcomes when CHF patients with nutritional risk received individualized nutritional treatment. Objective To estimate the cost-effectiveness of individualized nutritional support in hospitalized patients with CHF. Methods This analysis used data from CHF patients at risk of malnutrition (N = 645) who were part of the Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial (EFFORT). Study patients with CHF were randomized into (i) an intervention group (individualized nutritional support to reach energy, protein, and micronutrient goals) or (ii) a control group (receiving standard hospital food). We used a Markov model with daily cycles (over a 6-month interval) to estimate hospital costs and health outcomes in the comparator groups, thus modeling cost-effectiveness ratios of nutritional interventions. Results With nutritional support, the modeled total additional cost over the 6-month interval was 15,159 Swiss Francs (SF). With an additional 5.77 life days, the overall incremental cost-effectiveness ratio for nutritional support vs. no nutritional support was 2625 SF per life day gained. In terms of complications, patients receiving nutritional support had a cost savings of 6214 SF and an additional 4.11 life days without complications, yielding an incremental cost-effectiveness ratio for avoided complications of 1513 SF per life day gained. Conclusions On the basis of a Markov model, this economic analysis found that in-hospital nutritional support for CHF patients increased life expectancy at an acceptable incremental cost-effectiveness ratio.
- Open Access
- 1 January 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Tackling the care crisis in PD in East-Saxony, Germany - #Improve diagnosis and therapy in Parkinson's disease #Telemedicine-based care management #Intersectoral and interdisciplinary collaboration #Cost containment and quality improvement
- 1 January 2018
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 18 (s2)
Open AccessTackling the care crisis in PD in East-Saxony, Germany - #Improve diagnosis and therapy in Parkinson's disease #Telemedicine-based care management #Intersectoral and interdisciplinary collaboration #Cost containment and quality improvement
- 11 June 2016
- Published by Springer Nature
- p. 205-234
Vergütungshöhe und Preissetzung
- 24 September 2014
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (1) , 121-128
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy
(2015). Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Review of Anticancer Therapy: Vol. 15, No. 1, pp. 121-128.
- 24 September 2014
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (1) , 121-128
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy
(2015). Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Review of Anticancer Therapy: Vol. 15, No. 1, pp. 121-128.